- Home
- VOR
as 10-20-2025 3:55pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 207.1M | IPO Year: | 2021 |
| Target Price: | $85.33 | AVG Volume (30 days): | 526.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -342.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $65.80 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vor Biopharma Inc. (VOR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 17 '25 | Sell | $30.13 | 260,859 | $7,667,443.80 | 1,546,621 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 16 '25 | Sell | $30.34 | 151,803 | $4,470,604.04 | 1,546,621 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 15 '25 | Sell | $30.86 | 51,363 | $1,569,313.25 | 1,546,621 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 14 '25 | Sell | $30.32 | 33,668 | $1,020,786.83 | 1,278,118 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 13 '25 | Sell | $32.72 | 22,006 | $713,786.10 | 1,278,118 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 10 '25 | Sell | $30.97 | 40,983 | $1,269,132.86 | 1,278,118 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 9 '25 | Sell | $32.16 | 48,884 | $1,567,611.36 | 1,278,118 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 8 '25 | Sell | $34.05 | 75,262 | $2,548,757.17 | 1,278,118 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 7 '25 | Sell | $33.84 | 27,624 | $934,710.53 | 1,278,118 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 6 '25 | Sell | $36.97 | 70,763 | $2,618,788.10 | 1,278,118 |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
Argus Research
17 hours ago
Daily – Vickers Top Buyers & Sellers for 10/20/2025
TipRanks
4 days ago
Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint
GlobeNewswire
4 days ago
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
GlobeNewswire
5 days ago
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Argus Research
5 days ago
Daily – Vickers Top Buyers & Sellers for 10/16/2025
MT Newswires
7 days ago
Vor Biopharma Says Telitacicept Meets Primary, All Secondary Endpoints in China Late-Stage Autoimmune Disease Trial
GlobeNewswire
7 days ago
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
Argus Research
8 days ago
Daily – Vickers Top Buyers & Sellers for 10/13/2025
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.